Synlogic Inc (NASDAQ:SYBX) insider Paul Francis Miller sold 3,000 shares of the company’s stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $13.05, for a total value of $39,150.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Paul Francis Miller also recently made the following trade(s):

  • On Wednesday, September 5th, Paul Francis Miller sold 3,000 shares of Synlogic stock. The shares were sold at an average price of $12.55, for a total value of $37,650.00.
  • On Thursday, August 30th, Paul Francis Miller sold 3,000 shares of Synlogic stock. The shares were sold at an average price of $9.76, for a total value of $29,280.00.
  • On Wednesday, July 18th, Paul Francis Miller sold 3,000 shares of Synlogic stock. The shares were sold at an average price of $11.01, for a total value of $33,030.00.

Synlogic stock traded down $0.37 during mid-day trading on Friday, hitting $9.74. 145,115 shares of the company were exchanged, compared to its average volume of 137,510. Synlogic Inc has a 1-year low of $7.27 and a 1-year high of $18.36. The firm has a market capitalization of $361.37 million, a P/E ratio of -1.66 and a beta of 1.69.

Synlogic (NASDAQ:SYBX) last posted its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.06). The firm had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.22 million. Synlogic had a negative net margin of 5,949.04% and a negative return on equity of 43.51%. On average, sell-side analysts forecast that Synlogic Inc will post -2.47 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Synlogic during the first quarter worth about $120,000. Spark Investment Management LLC raised its position in shares of Synlogic by 72.5% during the first quarter. Spark Investment Management LLC now owns 18,800 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 7,900 shares during the period. DRW Securities LLC acquired a new stake in shares of Synlogic during the first quarter worth about $178,000. Element Capital Management LLC acquired a new stake in Synlogic in the 1st quarter valued at approximately $182,000. Finally, Deutsche Bank AG raised its position in Synlogic by 204.0% in the 4th quarter. Deutsche Bank AG now owns 19,672 shares of the biotechnology company’s stock valued at $190,000 after buying an additional 13,200 shares during the last quarter. 79.39% of the stock is currently owned by institutional investors.

A number of research analysts recently commented on the company. Citigroup upgraded Synlogic from a “neutral” rating to a “buy” rating in a research note on Friday, August 24th. HC Wainwright set a $20.00 price objective on Synlogic and gave the stock a “buy” rating in a research note on Thursday, August 9th. reiterated a “buy” rating and set a $18.00 price objective on shares of Synlogic in a research note on Tuesday, July 3rd. Oppenheimer began coverage on Synlogic in a research note on Friday, June 29th. They set an “outperform” rating and a $18.00 price objective for the company. Finally, Zacks Investment Research lowered Synlogic from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $17.93.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Read More: What is the NASDAQ Stock Market?

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.